The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul).
 
Uta Dirksen
No Relationships to Disclose
 
Marie-Cecile Le Deley
No Relationships to Disclose
 
Bernadette Brennan
No Relationships to Disclose
 
Ian Robert Judson
Honoraria - Ariad; Bayer; GlaxoSmithKline; GlaxoSmithKline; Merck Serono
Consulting or Advisory Role - ARIAD; Bayer; GlaxoSmithKline
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Merck Serono
 
Mark L. Bernstein
Research Funding - Merck
 
Richard Greg Gorlick
No Relationships to Disclose
 
Neyssa Marina
No Relationships to Disclose
 
Richard B. Womer
No Relationships to Disclose
 
Nathalie Cozic
No Relationships to Disclose
 
Nathalie Gaspar
No Relationships to Disclose
 
Gwenael Le Teuff
No Relationships to Disclose
 
Perrine Marec-Berard
No Relationships to Disclose
 
Andreas Faldum
No Relationships to Disclose
 
Michael Paulussen
No Relationships to Disclose
 
Herbert Juergens
No Relationships to Disclose
 
Lars Hjorth
No Relationships to Disclose
 
Keith Wheatley
No Relationships to Disclose
 
Mark D. Krailo
No Relationships to Disclose
 
Jeremy Whelan
No Relationships to Disclose
 
Douglas S. Hawkins
No Relationships to Disclose